Pallas Capital Advisors LLC Raises Position in Danaher Co. (NYSE:DHR)

Pallas Capital Advisors LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 132.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 19,278 shares of the conglomerate’s stock after acquiring an additional 10,976 shares during the period. Pallas Capital Advisors LLC’s holdings in Danaher were worth $4,425,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in DHR. Coronation Fund Managers Ltd. increased its stake in Danaher by 29.9% in the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after acquiring an additional 1,470 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Danaher by 4.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,004 shares of the conglomerate’s stock valued at $6,247,000 after buying an additional 957 shares in the last quarter. Parallel Advisors LLC boosted its stake in Danaher by 3.4% in the second quarter. Parallel Advisors LLC now owns 13,524 shares of the conglomerate’s stock worth $3,379,000 after buying an additional 445 shares in the last quarter. Thoroughbred Financial Services LLC grew its position in Danaher by 124.1% during the second quarter. Thoroughbred Financial Services LLC now owns 1,956 shares of the conglomerate’s stock valued at $488,000 after acquiring an additional 1,083 shares during the last quarter. Finally, Wealthspire Advisors LLC raised its stake in shares of Danaher by 3.5% during the second quarter. Wealthspire Advisors LLC now owns 4,823 shares of the conglomerate’s stock worth $1,205,000 after acquiring an additional 165 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 2.0 %

Shares of NYSE:DHR traded up $4.76 during midday trading on Monday, reaching $239.83. The company’s stock had a trading volume of 3,299,741 shares, compared to its average volume of 2,915,061. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $235.67 and a 200-day moving average of $253.73. The firm has a market capitalization of $173.22 billion, a P/E ratio of 45.77, a PEG ratio of 4.32 and a beta of 0.83. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, research analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research reports. KeyCorp upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Barclays lowered their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price for the company. Finally, TD Cowen lifted their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.